A hearing on a motion by L’Oreal USA Inc. and other cosmetic companies challenging the claims by 15 plaintiffs that their bladder cancer was due to exposure to carcinogenic and endocrine-disrupting ...

The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

The regulatory landscape for ANKTIVA saw critical developments regarding bladder cancer. ImmunityBio reported on January 20th that it held a Type B End-of-Phase meeting with the U.S. Food and Drug ...

With $202.3M in cash and an expanded $125M debt facility, ENGN is financially equipped to advance pivotal Cohort 1 and pursue ...

IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

ANKTIVA is an Interleukin-15 (IL-15) receptor agonist that helps develop and activate key cells that work to destroy cancer cells. ・The company presented an overview of the clinical status of its ...

The MarketWatch News Department was not involved in the creation of this content. -- Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company’s supplemental ...